Halozyme Therapeutics, Inc.
HALO
$64.66
-$1.88-2.83%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.24B | 1.18B | 1.08B | 1.02B | 947.36M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.24B | 1.18B | 1.08B | 1.02B | 947.36M |
| Cost of Revenue | 232.98M | 228.37M | 221.62M | 201.66M | 212.80M |
| Gross Profit | 1.01B | 950.30M | 862.69M | 813.66M | 734.56M |
| SG&A Expenses | 172.31M | 167.47M | 161.56M | 154.34M | 149.69M |
| Depreciation & Amortization | 71.05M | 71.05M | 71.05M | 71.05M | 71.05M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 505.45M | 496.00M | 486.84M | 463.85M | 470.35M |
| Operating Income | 737.40M | 682.67M | 597.47M | 551.48M | 477.01M |
| Income Before Tax | 745.94M | 692.13M | 604.93M | 557.13M | 480.09M |
| Income Tax Expenses | 150.45M | 134.85M | 119.57M | 113.04M | 87.63M |
| Earnings from Continuing Operations | 595.49 | 557.28 | 485.36 | 444.09 | 392.47 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 595.49M | 557.28M | 485.36M | 444.09M | 392.47M |
| EBIT | 737.40M | 682.67M | 597.47M | 551.48M | 477.01M |
| EBITDA | 813.28M | 758.60M | 673.22M | 627.09M | 553.00M |
| EPS Basic | 4.90 | 4.48 | 3.86 | 3.50 | 3.08 |
| Normalized Basic EPS | 3.81 | 3.46 | 2.98 | 2.72 | 2.33 |
| EPS Diluted | 4.75 | 4.37 | 3.76 | 3.43 | 3.02 |
| Normalized Diluted EPS | 3.70 | 3.38 | 2.92 | 2.67 | 2.29 |
| Average Basic Shares Outstanding | 488.18M | 497.81M | 503.59M | 507.31M | 509.96M |
| Average Diluted Shares Outstanding | 502.11M | 509.92M | 514.98M | 517.22M | 519.28M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |